Why the study?
Does elevated platelet turnover predict major adverse cardiovascular events in patients after PCI on dual antiplatelet therapy?
Does elevated platelet turnover predict major adverse cardiovascular events in patients after PCI on dual antiplatelet therapy?
Reticulated platelet fraction (RPF) serves as an independent predictor of both MACE and bleeding events in patients undergoing PCI on dual antiplatelet therapy.
No takes yet. Share an insight, caveat, or question.
RPF may aid post-PCI risk stratification on DAPT; leaves open whether turnover-guided therapy improves outcomes.
Iliev et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: